Related Experiment Videos
New cytotoxic drugs and targets in oncology
1Hospital/Netherlands Cancer Institute, Amsterdam.
Abstract:
New agents in the preclinical and early clinical pipeline (phases I and II) are described and some of the problems associated with their development are reviewed. The article focuses on tubulin poisons such as taxol, topoisomerase inhibitors, such as topotecan, and drugs such as bryostatin 1 and miltefosin, which interfere with specific signal transduction pathways involved in malignant cell growth.
Insights
This review covers novel anticancer agents in early development, including tubulin poisons, topoisomerase inhibitors, and signal transduction pathway modulators. It also discusses challenges in bringing these new cancer drugs to patients.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- The pipeline for new cancer therapies is crucial for advancing patient care.
- Many promising agents face significant hurdles during preclinical and early clinical development.
Purpose of the Study:
- To review novel anticancer agents currently in the preclinical and early clinical phases (I and II).
- To identify and discuss common problems encountered during the development of these new cancer drugs.
Main Methods:
- Literature review of agents in the preclinical and early clinical pipeline.
- Focus on specific drug classes: tubulin poisons (e.g., paclitaxel), topoisomerase inhibitors (e.g., topotecan), and signal transduction pathway modulators (e.g., bryostatin 1, miltefosin).
Main Results:
- Identification of key drug candidates and their mechanisms of action.
- Discussion of challenges including efficacy, toxicity, and patient selection for novel therapeutics.
Conclusions:
- Several classes of novel anticancer agents show promise for malignant cell growth inhibition.
- Addressing development challenges is essential for successful translation of these agents into clinical practice.